References
- Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
- Notelovitz M. Urogenital atrophy and low-dose vaginal estrogen therapy. Menopause 2000;7:140–2
- Stenberg A, Heimer G, Ulmsten U, Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 1996;24:31–6
- Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83–92
- Willhite LA, O’Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001;21:464–80
- Bachmann GA Vulvovaginal complaints. In Lobo RA, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. New York: Raven Press, 1994: 137–42
- Management of symptomatic vulvovaginal atrophy: 2013position statement of The North American Menopause Society. Menopause 2013;20:888–902
- Caswell M, Kane M. Comparison of the moisturization efficacy of two vaginal moisturizers: Pectin versus polycarbophil technologies. J Cosmetic Sc 2002;53:81–7
- Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969–73
- Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259–63
- Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178–80
- Wellek S, Blettner M. Establishing equivalence or non-inferiority in clinical trials: part 20 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2012;109:674–9
- Parsons A, Merritt D, Rosen A, et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346–52
- Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26: 404–12
- Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marre GB. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. ArzneimittelForschung 2006;56:230–8
- Lima SM, Yamada SS, Reis BF, et al. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas 2013; 74:252–8
- Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sexual Med 2013;10:1575–84
- Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci 2008;12:411–16
- Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–60